



Pancreatic Cancer

Quick Reference Guide

2026

Table of Contents

1. CLINICAL SNAPSHOT	3
HCC/RAF V28 Mapping	3
2. RECOGNITION AND DIAGNOSIS	5
Diagnostic Workups Covered Under Medicare Part B (older adults, at-risk population)	5
Subtle Early Signs in Older Adults	6
Risk Factors	7
Diagnostic Tests and Pancreatic Cancer Staging Thresholds	8
Common Oversights	14
Key Differentials in Elderly	15
Comorbidity Screening	15
2026 NCCN Resectability Criteria For Localized Pancreatic Cancer	16
3. MEAT DOCUMENTATION ESSENTIALS	18
Clinical Documentation Elements	19
Reframing Common Documentation Shortcuts	19
4. TREATMENT AND REFERRAL QUICK GUIDE	20
NCCN-Aligned Therapy Selection and Escalation Criteria	21
Non-Pharmacologic Care and Supportive Interventions	22
Medication Safety and Key Interactions	22
When to Refer	23
Follow-Up Timing	24
Comorbidity Management — Primary Care Role	25
Cost-Smart Options	26
Quality Metrics Tie-In	27
5. CODING REMINDERS AND CASE EXAMPLES	30
Coding Specificity	30
Annual Clinical Review and Confirmation	31
Good Documentation is Comprehensive Coding	32
EHR Workflow Tips	33
Brief Case Examples	34
REFERENCES	35

1 CLINICAL SNAPSHOT

Definition: Pancreatic ductal adenocarcinoma (PDAC) is the most common malignant neoplasm of the pancreas (~90% of cases), arising from **exocrine ductal epithelial cells** with KRAS as the defining driver mutation in ~92% of tumors, followed by CDKN2A, TP53, and SMAD4 alterations.^{1,2} The natural history is aggressive and largely **asymptomatic in early stages**: approximately 80% of patients are diagnosed at locally advanced or metastatic disease when **curative resection is no longer feasible**, and the median age at diagnosis is 71 years, making PDAC particularly **relevant to older adults** in the Medicare population who often present with greater comorbidity burden, frailty, and complex care needs that affect treatment selection and outcomes.

ICD-10 Codes

Primary tumor: **C25.0** (head, ~60–70% of PDAC), **C25.1** (body), **C25.2** (tail), **C25.3** (duct), **C25.4** (endocrine pancreas — islet/adeno only; not PanNET), **C25.7** (other parts), **C25.8** (overlapping), **C25.9** (unspecified **AVOID when subsite is documentable**). Metastatic site coding (**each separately documented**): **C78.7** (liver = most common, ~75–80% of metastatic disease), **C78.89** (other digestive), **C78.6** (peritoneum), **C78.00–C78.02** (lung), **C79.51** (bone). **Comorbidities frequently co-documented:** exocrine pancreatic insufficiency (**EPI; K86.81**), diabetes mellitus (**DM**, secondary or pre-existing; **E11.x** or **E13.x**), deep vein thrombosis (**DVT; I82.4x**), pulmonary embolism (**PE; I26.x**), biliary obstruction (**K83.1**), depression (**F32.x**), malnutrition (**E44.0/E43**), weight loss (**R63.4**). Personal history Z-code (**Z85.07**) applies only **after treatment completion** with no evidence of active disease = never during active treatment or surveillance.

Prevalence and Burden: Approximately **66,440 new cases** and **51,750 pancreatic cancer-related deaths** are projected in the United States in 2026.³ Pancreatic cancer is the 10th most common cancer by incidence and the **3rd leading cause of cancer death**.³ The 5-year relative survival across all stages is less than 13%; ~44% for localized disease, ~15% for regional, and ~3% for distant disease.³ Up to 50% of patients with newly diagnosed pancreatic cancer have diabetes at diagnosis;^{4,5} new-onset diabetes ≥50 years carries an adjusted HR of 9.07 (95% CI 8.33–9.87) for PDAC diagnosis within 1 year. Slight male predominance (M:F ~1.3:1); modestly higher incidence in Black Americans than White Americans.² There is currently no recommended population-wide screening strategy for pancreatic cancer (**USPSTF Grade D recommendation**); therefore, early recognition relies largely on **pattern-based clinical suspicion**, particularly in patients with unexplained weight loss and new-onset diabetes later in life.

HCC/RAF V28 Mapping

ICD-10 CODE(S) ⁶	HCC CATEGORY (V28) ⁷	RAF (CNA) ⁸	DOCUMENTATION REQUIREMENT
C25.0–C25.8 (specific subsite)	HCC 20 Lung and Other Severe Cancers	1.136	Document active malignancy confirmed by pathology or imaging with anatomic subsite from the imaging or pathology report: head, body, tail, duct, endocrine, other, or overlapping; record histologic confirmation (EUS-FNB preferred over CT-guided biopsy for non-metastatic disease)

AAVBC Knowledge Hub Premium Content Access

Continue reading your guide
with an AAVBC subscription

[Subscribe Now](#)

Already a subscriber? [Sign in](#)

Limited offer

Basic Membership

Free

Includes access to downloadable Quick Reference Guides, mailing list for industry updates/medical information, research toolkits, AAVBC events and so much more!

Cancel at any time